Report Detail

Pharma & Healthcare Global DTaP and Tdap Vaccines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

  • RnM4592440
  • |
  • 05 June, 2024
  • |
  • Global
  • |
  • 121 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global DTaP and Tdap Vaccines market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the DTaP and Tdap Vaccines industry chain, the market status of Adult (DTaP, Td), Pediatric (DTaP, Td), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of DTaP and Tdap Vaccines.
Regionally, the report analyzes the DTaP and Tdap Vaccines markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global DTaP and Tdap Vaccines market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the DTaP and Tdap Vaccines market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the DTaP and Tdap Vaccines industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., DTaP, Td).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the DTaP and Tdap Vaccines market.
Regional Analysis: The report involves examining the DTaP and Tdap Vaccines market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the DTaP and Tdap Vaccines market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to DTaP and Tdap Vaccines:
Company Analysis: Report covers individual DTaP and Tdap Vaccines manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards DTaP and Tdap Vaccines This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adult, Pediatric).
Technology Analysis: Report covers specific technologies relevant to DTaP and Tdap Vaccines. It assesses the current state, advancements, and potential future developments in DTaP and Tdap Vaccines areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the DTaP and Tdap Vaccines market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
DTaP and Tdap Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
DTaP
Td
Tdap
Market segment by Application
Adult
Pediatric
Major players covered
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe DTaP and Tdap Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of DTaP and Tdap Vaccines, with price, sales, revenue and global market share of DTaP and Tdap Vaccines from 2019 to 2024.
Chapter 3, the DTaP and Tdap Vaccines competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the DTaP and Tdap Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and DTaP and Tdap Vaccines market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of DTaP and Tdap Vaccines.
Chapter 14 and 15, to describe DTaP and Tdap Vaccines sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of DTaP and Tdap Vaccines
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 DTaP
    • 1.3.3 Td
    • 1.3.4 Tdap
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Adult
    • 1.4.3 Pediatric
  • 1.5 Global DTaP and Tdap Vaccines Market Size & Forecast
    • 1.5.1 Global DTaP and Tdap Vaccines Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global DTaP and Tdap Vaccines Sales Quantity (2019-2030)
    • 1.5.3 Global DTaP and Tdap Vaccines Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Sanofi Pasteur
    • 2.1.1 Sanofi Pasteur Details
    • 2.1.2 Sanofi Pasteur Major Business
    • 2.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Product and Services
    • 2.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Sanofi Pasteur Recent Developments/Updates
  • 2.2 GlaxoSmithKline
    • 2.2.1 GlaxoSmithKline Details
    • 2.2.2 GlaxoSmithKline Major Business
    • 2.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Product and Services
    • 2.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 GlaxoSmithKline Recent Developments/Updates
  • 2.3 Protein Sciences Corporation
    • 2.3.1 Protein Sciences Corporation Details
    • 2.3.2 Protein Sciences Corporation Major Business
    • 2.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Product and Services
    • 2.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Protein Sciences Corporation Recent Developments/Updates
  • 2.4 Novartis AG
    • 2.4.1 Novartis AG Details
    • 2.4.2 Novartis AG Major Business
    • 2.4.3 Novartis AG DTaP and Tdap Vaccines Product and Services
    • 2.4.4 Novartis AG DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Novartis AG Recent Developments/Updates
  • 2.5 Seqirus
    • 2.5.1 Seqirus Details
    • 2.5.2 Seqirus Major Business
    • 2.5.3 Seqirus DTaP and Tdap Vaccines Product and Services
    • 2.5.4 Seqirus DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Seqirus Recent Developments/Updates
  • 2.6 Merck Sharp & Dohme Corp
    • 2.6.1 Merck Sharp & Dohme Corp Details
    • 2.6.2 Merck Sharp & Dohme Corp Major Business
    • 2.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product and Services
    • 2.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates
  • 2.7 Astellas Pharma US, Inc
    • 2.7.1 Astellas Pharma US, Inc Details
    • 2.7.2 Astellas Pharma US, Inc Major Business
    • 2.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product and Services
    • 2.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Astellas Pharma US, Inc Recent Developments/Updates
  • 2.8 Pfizer Inc
    • 2.8.1 Pfizer Inc Details
    • 2.8.2 Pfizer Inc Major Business
    • 2.8.3 Pfizer Inc DTaP and Tdap Vaccines Product and Services
    • 2.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Pfizer Inc Recent Developments/Updates
  • 2.9 Johnson & Johnson
    • 2.9.1 Johnson & Johnson Details
    • 2.9.2 Johnson & Johnson Major Business
    • 2.9.3 Johnson & Johnson DTaP and Tdap Vaccines Product and Services
    • 2.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Johnson & Johnson Recent Developments/Updates
  • 2.10 Lanzhou Institute of Biological Products Co., Ltd
    • 2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
    • 2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
    • 2.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product and Services
    • 2.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
  • 2.11 AstraZeneca
    • 2.11.1 AstraZeneca Details
    • 2.11.2 AstraZeneca Major Business
    • 2.11.3 AstraZeneca DTaP and Tdap Vaccines Product and Services
    • 2.11.4 AstraZeneca DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 AstraZeneca Recent Developments/Updates
  • 2.12 Emergent BioSolutions Inc
    • 2.12.1 Emergent BioSolutions Inc Details
    • 2.12.2 Emergent BioSolutions Inc Major Business
    • 2.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product and Services
    • 2.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Emergent BioSolutions Inc Recent Developments/Updates

3 Competitive Environment: DTaP and Tdap Vaccines by Manufacturer

  • 3.1 Global DTaP and Tdap Vaccines Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global DTaP and Tdap Vaccines Revenue by Manufacturer (2019-2024)
  • 3.3 Global DTaP and Tdap Vaccines Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of DTaP and Tdap Vaccines by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
    • 3.4.2 Top 6 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
  • 3.5 DTaP and Tdap Vaccines Market: Overall Company Footprint Analysis
    • 3.5.1 DTaP and Tdap Vaccines Market: Region Footprint
    • 3.5.2 DTaP and Tdap Vaccines Market: Company Product Type Footprint
    • 3.5.3 DTaP and Tdap Vaccines Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global DTaP and Tdap Vaccines Market Size by Region
    • 4.1.1 Global DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
    • 4.1.2 Global DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
    • 4.1.3 Global DTaP and Tdap Vaccines Average Price by Region (2019-2030)
  • 4.2 North America DTaP and Tdap Vaccines Consumption Value (2019-2030)
  • 4.3 Europe DTaP and Tdap Vaccines Consumption Value (2019-2030)
  • 4.4 Asia-Pacific DTaP and Tdap Vaccines Consumption Value (2019-2030)
  • 4.5 South America DTaP and Tdap Vaccines Consumption Value (2019-2030)
  • 4.6 Middle East and Africa DTaP and Tdap Vaccines Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 5.2 Global DTaP and Tdap Vaccines Consumption Value by Type (2019-2030)
  • 5.3 Global DTaP and Tdap Vaccines Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 6.2 Global DTaP and Tdap Vaccines Consumption Value by Application (2019-2030)
  • 6.3 Global DTaP and Tdap Vaccines Average Price by Application (2019-2030)

7 North America

  • 7.1 North America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 7.2 North America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 7.3 North America DTaP and Tdap Vaccines Market Size by Country
    • 7.3.1 North America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
    • 7.3.2 North America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 8.2 Europe DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 8.3 Europe DTaP and Tdap Vaccines Market Size by Country
    • 8.3.1 Europe DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific DTaP and Tdap Vaccines Market Size by Region
    • 9.3.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 10.2 South America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 10.3 South America DTaP and Tdap Vaccines Market Size by Country
    • 10.3.1 South America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
    • 10.3.2 South America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa DTaP and Tdap Vaccines Market Size by Country
    • 11.3.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 DTaP and Tdap Vaccines Market Drivers
  • 12.2 DTaP and Tdap Vaccines Market Restraints
  • 12.3 DTaP and Tdap Vaccines Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of DTaP and Tdap Vaccines and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of DTaP and Tdap Vaccines
  • 13.3 DTaP and Tdap Vaccines Production Process
  • 13.4 DTaP and Tdap Vaccines Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 DTaP and Tdap Vaccines Typical Distributors
  • 14.3 DTaP and Tdap Vaccines Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on DTaP and Tdap Vaccines. Industry analysis & Market Report on DTaP and Tdap Vaccines is a syndicated market report, published as Global DTaP and Tdap Vaccines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of DTaP and Tdap Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,756.16
    4,134.24
    5,512.32
    3,253.80
    4,880.70
    6,507.60
    556,243.20
    834,364.80
    1,112,486.40
    290,962.80
    436,444.20
    581,925.60
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report